143 related articles for article (PubMed ID: 32620664)
1. C-Reactive Protein and Absolute Lymphocyte Count Can Predict Overall Survival of Patients Treated With Eribulin.
Sata A; Fukui R; Miyagawa Y; Bun A; Ozawa H; Fujimoto Y; Higuchi T; Imamura M; Miyoshi Y
Anticancer Res; 2020 Jul; 40(7):4147-4156. PubMed ID: 32620664
[TBL] [Abstract][Full Text] [Related]
2. Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer.
Goto W; Kashiwagi S; Takada K; Asano Y; Morisaki T; Shibutani M; Tanaka H; Hirakawa K; Ohira M
Anticancer Res; 2022 Feb; 42(2):939-946. PubMed ID: 35093893
[TBL] [Abstract][Full Text] [Related]
3. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study.
Miyoshi Y; Yoshimura Y; Saito K; Muramoto K; Sugawara M; Alexis K; Nomoto K; Nakamura S; Saeki T; Watanabe J; Perez-Garcia JM; Cortes J
Breast Cancer; 2020 Jul; 27(4):706-715. PubMed ID: 32133606
[TBL] [Abstract][Full Text] [Related]
4. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y
BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862
[TBL] [Abstract][Full Text] [Related]
5. Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel.
Miyagawa Y; Araki K; Bun A; Ozawa H; Fujimoto Y; Higuchi T; Nishimukai A; Kira A; Imamura M; Takatsuka Y; Miyoshi Y
Clin Breast Cancer; 2018 Oct; 18(5):400-409. PubMed ID: 29605174
[TBL] [Abstract][Full Text] [Related]
6. Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin.
Su MX; Lin HW; Nguyen HTH; Lin TC; Chen CJ; Wang HC; Wu CT; Wu YC; He GY; Liu LC; Huang CH
BMC Cancer; 2024 Feb; 24(1):195. PubMed ID: 38347468
[TBL] [Abstract][Full Text] [Related]
7. Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan.
Takahashi M; Inoue K; Mukai H; Yamanaka T; Egawa C; Miyoshi Y; Sakata Y; Muramoto K; Ikezawa H; Matsuoka T; Tsurutani J
Breast Cancer; 2021 Jul; 28(4):945-955. PubMed ID: 33677779
[TBL] [Abstract][Full Text] [Related]
8. A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience.
Watanabe J; Saito M; Horimoto Y; Nakamoto S
Breast Cancer Res Treat; 2020 May; 181(1):211-220. PubMed ID: 32249370
[TBL] [Abstract][Full Text] [Related]
9. Dynamic Changes in Absolute Lymphocyte Counts During Eribulin Therapy Are Associated With Survival Benefit.
Nakamoto S; Ikeda M; Kubo S; Yamamoto M; Yamashita T
Anticancer Res; 2021 Jun; 41(6):3109-3119. PubMed ID: 34083304
[TBL] [Abstract][Full Text] [Related]
10. Utility of the Absolute Lymphocyte Count and Neutrophil/Lymphocyte Ratio for Predicting Survival in Patients with Metastatic Breast Cancer on Eribulin: A Real-World Observational Study.
Ueno A; Maeda R; Kin T; Ito M; Kawasaki K; Ohtani S
Chemotherapy; 2019; 64(5-6):259-269. PubMed ID: 32305977
[TBL] [Abstract][Full Text] [Related]
11. Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma.
Sato Y; Nakano K; Fukuda N; Wang X; Urasaki T; Ohmoto A; Yunokawa M; Ono M; Tomomatsu J; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S
Anticancer Res; 2021 Jan; 41(1):527-532. PubMed ID: 33419852
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Nutritional Index Is Superior to Neutrophil-to-lymphocyte Ratio as a Prognostic Marker in Metastatic Breast Cancer Patients Treated With Eribulin.
Oba T; Maeno K; Ono M; Ito T; Kanai T; Ito KI
Anticancer Res; 2021 Jan; 41(1):445-452. PubMed ID: 33419842
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancer.
Myojin M; Horimoto Y; Ito M; Kitano S; Ishizuka Y; Sasaki R; Uomori T; Himuro T; Murakami F; Nakai K; Iijima K; Saito M
Breast Cancer; 2020 Jul; 27(4):732-738. PubMed ID: 32108306
[TBL] [Abstract][Full Text] [Related]
14. Validation of Systemic and Local Tumour Immune Response to Eribulin Chemotherapy in the Treatment of Breast Cancer.
Kashiwagi S; Asano Y; Goto W; Takada K; Morisaki T; Kouhashi R; Yabumoto A; Tanaka S; Takashima T; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2020 Jun; 40(6):3345-3354. PubMed ID: 32487630
[TBL] [Abstract][Full Text] [Related]
15. Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types.
Morisaki T; Kashiwagi S; Asano Y; Goto W; Takada K; Ishihara S; Shibutani M; Tanaka H; Hirakawa K; Ohira M
World J Surg Oncol; 2021 Nov; 19(1):324. PubMed ID: 34775950
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study.
Takamizawa S; Shimoi T; Satomi-Tsushita N; Yazaki S; Okuya T; Kojima Y; Sumiyoshi-Okuma H; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Yonemori K
BMC Cancer; 2022 Jan; 22(1):64. PubMed ID: 35027011
[TBL] [Abstract][Full Text] [Related]
17. [Study of the Therapeutic Effect and Neutrophil Lymphocyte Ratio in Breast Cancer Patients Who Received Eribulin].
Kubota H; Adachi K; Suzuki S; Hara Y; Fujisaki S; Tomita R; Enomoto K; Hirano T; Sakurai K
Gan To Kagaku Ryoho; 2018 Oct; 45(10):1492-1494. PubMed ID: 30382055
[TBL] [Abstract][Full Text] [Related]
18. Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.
Kanaoka H; Nagahashi M; Atake Y; Hattori A; Bun A; Fukui R; Ozawa H; Fujimoto Y; Higuchi T; Natori K; Imamura M; Murase K; Takatsuka Y; Miyoshi Y
Anticancer Res; 2022 Oct; 42(10):4867-4878. PubMed ID: 36192009
[TBL] [Abstract][Full Text] [Related]
19. Absolute Lymphocyte Count, Platelet-to-Lymphocyte Ratio, and Overall Survival in Eribulin-treated HER2-negative Metastatic Breast Cancer Patients.
Koyama Y; Kawai S; Uenaka N; Okazaki M; Asaoka M; Teraoka S; Ueda AI; Miyahara K; Kawate T; Kaise H; Yamada K; Ishikawa T
Cancer Diagn Progn; 2021; 1(5):435-441. PubMed ID: 35403160
[TBL] [Abstract][Full Text] [Related]
20. Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer.
Miyagawa Y; Yanai A; Yanagawa T; Inatome J; Egawa C; Nishimukai A; Takamoto K; Morimoto T; Kikawa Y; Suwa H; Taji T; Yamaguchi A; Okada Y; Sata A; Fukui R; Bun A; Ozawa H; Higuchi T; Fujimoto Y; Imamura M; Miyoshi Y
Oncotarget; 2020 Jan; 11(1):86-98. PubMed ID: 32002126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
